Mp15-10 Discovery of Tbk1 Associated Oncogenic Mechanism Which Mediates the Upper-Tract Urothelial Carcinoma With Preexisting End Stage Renal Disease

You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology I (MP15)1 May 2024MP15-10 DISCOVERY OF TBK1 ASSOCIATED ONCOGENIC MECHANISM WHICH MEDIATES THE UPPER-TRACT UROTHELIAL CARCINOMA WITH PREEXISTING END STAGE RENAL DISEASE Yu-Pin Huang, Eric Yi-Hsiu Huang, Yu-Ching Peng, Yu-Kuang Chen, William J. Huang, and Kung-Hao Liang Yu-Pin HuangYu-Pin Huang , Eric Yi-Hsiu HuangEric Yi-Hsiu Huang , Yu-Ching PengYu-Ching Peng , Yu-Kuang ChenYu-Kuang Chen , William J. HuangWilliam J. Huang , and Kung-Hao LiangKung-Hao Liang View All Author Informationhttps://doi.org/10.1097/01.JU.0001009500.87761.bf.10AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Upper urinary tract urothelial carcinoma (UTUC) represents one aggressive class of malignancy with higher incidence in Taiwan than the global average. The distinct demographics showed possibly different etiologies and suggested different molecular mechanisms which warrant local investigations. Meanwhile, the prevalence of patients with end stage renal disease (ESRD), indicated by the treatment of hemodialysis, is also higher than other countries. Furthermore, the incidence of UTUC in ESRD patients is much higher than patients without ESRD. We hypothesized that patients with ESRD and subsequent UTUC may have distinct oncogenic mechanism than the those without ESRD. METHODS: We obtained 50 fresh frozen tumor tissues of UTUC patients preserved in the biobank of our institute and performed transcriptomic profiling by RNAseq (IRB number: 2022-07-046BC). Among the 50 UTUC patients, 17 patients are ESRD patients under hemodialysis, while the other 33 patients are not ESRD. The molecular difference between ESRD and non-ESRD UTUC patients were investigated. Additionally, a total of 13 formalin-fixed paraffin-embedded slides were employed for immunohistochemical staining, with the goal of confirming the observed mechanism obtained from multi-omics investigation. RESULTS: The overall and cancer-specific survival were not different between ESRD and non-ESRD patients. We discovered that TBK1 mediated oncogenic pathway underlies UTUC patients with ESRD in contrast to those without ESRD. Additionally, the representative proteins of TBK1 mediated oncogenic pathway, such as NLK are higher in UTUC patients with ESRD. CONCLUSIONS: TBK1 and its epigenetic effects might be the oncogenic mechanisms underlying UTUC patients with ESRD. Download PPTDownload PPT Source of Funding: Nil © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e232 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Yu-Pin Huang More articles by this author Eric Yi-Hsiu Huang More articles by this author Yu-Ching Peng More articles by this author Yu-Kuang Chen More articles by this author William J. Huang More articles by this author Kung-Hao Liang More articles by this author Expand All Advertisement PDF downloadLoading ...